FindTrial
Sign In

N/A - C-HLH=

Status
Unknown
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2014-005585-30-FR
Enrollment
Unknown
Registered
2015-05-18
Start date
Unknown
Completion date
Unknown
Last updated
2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 18.0 Level: LLT Classification code 10070916 Term: Familial hemophagocytic lymphohistiocytosis System Organ Class: 100000004850

Interventions

Trade Name: MABCAMPATH Product Name: MABCAMPATH Product Code: code ATC:L01XC04 Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: Alemtuzumab CAS Number: 216503-57-0 Curr

Sponsors

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

France

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026